Group 1: Financial Performance Highlights - Lante Optics achieved a revenue of 1.536 billion yuan in 2025, a year-on-year increase of 48.52%, with a net profit of 388 million yuan, up 76.09% [1] - United Imaging reported a revenue of 13.82 billion yuan for 2025, reflecting a 34.18% year-on-year growth, and a net profit of 1.888 billion yuan, up 49.60% [2] - Hengxuan Technology's revenue reached 3.525 billion yuan, an 8.02% increase, with a net profit of 588 million yuan, up 27.75% [3] - Nanya New Materials reported a significant net profit increase of 378.65%, reaching 241 million yuan, with revenue of 5.228 billion yuan, up 55.52% [4] - Yancoal Australia, a subsidiary of Yancoal Energy, reported a revenue of 5.949 billion AUD and a net profit of 4.4 billion AUD for 2025 [5] - Hanlan Co. reported a revenue of 10.467 billion yuan, a 13.04% increase, but a net profit decline of 9.59% to 592 million yuan [10][11] - Transsion Holdings experienced a revenue decline of 4.50% to 65.623 billion yuan, with a net profit drop of 53.43% to 2.584 billion yuan [14] - Huachuang Technology achieved a revenue of 628 million yuan, a 2.78% increase, with a net profit of 42.678 million yuan, up 89.45% [21] - Aiko Optoelectronics reported a revenue of 440.311 million yuan, a 77.36% increase, with a net profit of 64.0919 million yuan, up 307.63% [34] - Chip Microelectronics achieved a revenue of 1.408 billion yuan, a 47.61% increase, with a net profit of 290 million yuan, up 80.42% [35] - Shenkong Co. reported a revenue of 443 million yuan, a 46.26% increase, with a net profit of 101 million yuan, up 146.54% [36] - Qinda Environmental reported a revenue of 2.042 billion yuan, a 55.42% increase, with a net profit of 181 million yuan, up 94.62% [39] Group 2: Corporate Developments - Huilong New Materials announced that its actual controller is planning a significant matter that may lead to a change in company control, resulting in a stock suspension [6] - Fangzheng Securities disclosed that its shareholder China Cinda did not reduce its shareholding as planned during the designated period [7] - Lingyi Technology plans to invest 20 million yuan in a partnership with several investment firms [8] - Longbai Group's subsidiary has partially resumed production after a safety incident [9] - Fuda Co. plans to reduce its repurchased shares by up to 1% through centralized bidding [13] - Fuxing Pharmaceutical's subsidiary received approval for clinical trials of a new drug for lung cancer [15] - Beixin Road and Bridge won a bid for a highway reconstruction project worth 751 million yuan [16] - Songsheng Co. established a joint venture with a registered capital of 30 million yuan, focusing on digital energy products [17] - Moxinlin reported a revenue of 577 million yuan, a 20.98% increase, with a net profit of 55.8745 million yuan, up 22.69% [18] - Zhuhai Beer reported a revenue of 5.878 billion yuan, a 2.56% increase, with a net profit of 903 million yuan, up 11.42% [24] - Honghua Digital reported a revenue of 2.308 billion yuan, a 28.90% increase, with a net profit of 529 million yuan, up 27.63% [25] - Xinfeng Pharmaceutical received FDA approval for two injectable drugs [26] - Jiazhe New Energy's project for green hydrogen production received regulatory approval [27] - Chip Microelectronics reported a revenue of 5.24 billion yuan, a 29.48% increase, with a net profit of 302 million yuan, up 36.1% [28] - Debang Co. completed the cash settlement process for its delisting [29] - Xingfu Electronics reported a revenue of 1.475 billion yuan, a 29.72% increase, with a net profit of 208 million yuan, up 30.37% [30] - Longda Food announced the resignation of its general manager due to work adjustments [31] - Bohai Chemical reported that some fundraising projects have commenced production [32] - Shengke Communication reported a net loss of 150 million yuan for 2025 [33] - Jin Cheng Pharmaceutical's subsidiaries received drug registration certificates for two products [37] - Jinpu Titanium Industry announced the resumption of production at its subsidiary [38] - Zhigao Electric's subsidiary won a bid for a project worth 182 million yuan [40]

Core Viewpoint - The company has successfully obtained a drug production license from the Henan Provincial Drug Administration for its subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd, indicating that its coenzyme Q10 raw material products are now compliant for production [1] Group 1 - The license acquisition marks a significant milestone for the company, allowing it to produce coenzyme Q10 related products legally [1] - The approval enhances the company's production capabilities and positions it favorably in the market for coenzyme Q10 [1]

智通财经APP讯，拓新药业(301089.SZ)公告，公司全资子公司新乡精泉生物技术有限公司(简称"精泉生 物")近日顺利取得了河南省药品监督管理局核发的《药品生产许可证》。该资质的获得，标志着公司辅 酶Q10原料药相关产品已正式具备合规生产的资质条件。 ...

格隆汇2月25日丨拓新药业(301089.SZ)公布，全资子公司新乡精泉生物技术有限公司（简称"精泉生 物"）近日顺利取得了河南省药品监督管理局核发的《药品生产许可证》。精泉生物本次系首次取得 《药品生产许可证》，该资质的获得，标志着公司辅酶Q10原料药相关产品已正式具备合规生产的资质 条件，符合药品生产的行业监管要求。本次资质落地将进一步丰富并优化公司的产品结构，对公司大健 康业务板块的布局与长远发展具有重要的积极推动作用。 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has obtained a drug production license from the Henan Provincial Drug Administration, which allows for the compliant production of Coenzyme Q10 raw materials, positively impacting the company's health business segment and long-term development [1] Group 1 - The license number issued is 豫20260007, and the production address is located at 266 Jingquan East Road, Xinxiang High-tech Zone, Henan Province [1] - The approval signifies that the company's related products for Coenzyme Q10 raw materials now meet the necessary compliance production qualifications [1] - This development is expected to enhance the company's strategic positioning in the health sector and support its long-term growth initiatives [1]

Core Viewpoint - The acquisition of the Drug Production License by the subsidiary of Tuoxin Pharmaceutical marks a significant milestone, enabling the company to produce Coenzyme Q10 raw materials in compliance with industry regulations, which is expected to enhance its product structure and support long-term growth in the health sector [1] Group 1 - Tuoxin Pharmaceutical's wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained the Drug Production License from the Henan Provincial Drug Administration [1] - This is the first time Jingquan Biotechnology has received the Drug Production License, indicating that its products related to Coenzyme Q10 raw materials now meet the regulatory requirements for pharmaceutical production [1] - The acquisition of this license is anticipated to enrich and optimize the company's product structure, playing a crucial role in the development of its health business segment [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）之全资子公司新乡精泉生 物技术有限公司（以下简称"精泉生物"）近日顺利取得了河南省药品监督管理 局核发的《药品生产许可证》。相关资质信息及对公司的影响公告如下： 一、《药品生产许可证》的基本信息 企业名称：新乡精泉生物技术有限公司 统一社会信用代码：914110700MA9L9KWXJ 证券代码：301089 证券简称：拓新药业 公告编号：2026-005 拓新药业集团股份有限公司 关于子公司取得药品生产许可证的公告 二、本次取得许可证对公司的影响 精泉生物本次系首次取得《药品生产许可证》，该资质的获得，标志着公司 辅酶 Q10 原料药相关产品已正式具备合规生产的资质条件，符合药品生产的行业 监管要求。本次资质落地将进一步丰富并优化公司的产品结构，对公司大健康业 务板块的布局与长远发展具有重要的积极推动作用。 住所（经营场所）：河南省新乡市高新区静泉东路 266 号 许可证编号：豫 20260007 分类码：Dh 法定代表人：刘德前 企业负责人：刘德前 质量负责人：王 ...

Core Viewpoint - The company is closely monitoring developments in the international small nucleic acid field and is tracking the application progress of small nucleic acid drugs [1] Group 1: Core Business Focus - The company's core business is focused on the research, development, production, and sales of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates [1] - Key products include sodium cytidine diphosphate, ribavirin, cytarabine hydrochloride, and cytosine, which are widely used in antiviral, antitumor, and neurological medications [1] Group 2: Health and Functional Food Market - The company is actively expanding into the health functional food raw material market, with main products including L-α-glycerophosphocholine, coenzyme Q10, monohydrate creatine, and L-carnitine [1] Group 3: Future Strategy - The company plans to closely follow market demand changes and continuously increase R&D investment to enhance operational performance and intrinsic value [1]

Group 1 - The stock price of Tuoxin Pharmaceutical (301089) has shown a downward trend over the past 7 days, with a cumulative decline of 0.38% [1][2] - As of February 11, the stock price decreased from 29.32 yuan to 29.21 yuan, with a single-day drop of 0.31% and a trading volume of 29.9 million yuan [2] - Technical indicators suggest that the stock is in a weak zone, with the current price near the lower Bollinger Band and a MACD divergence value of -0.235 [2] Group 2 - The number of shareholders increased by 6.46% from January 20 to February 4, reaching a total of 17,500 shareholders, indicating fluctuations in share concentration [3] - The company has not released any significant announcements in the past week, but the 2025 earnings forecast, released on January 26, indicates an expected loss of 54 million to 73 million yuan, which represents a year-on-year increase in losses [3]

Rocket Launch - Huabao New Energy's outdoor power supply products have been widely applied in various high-difficulty off-grid power scenarios, including domestic rocket launches [1] - Taisheng Wind Power's rocket storage tank project is expected to officially start production by mid-2026 [1] Battery - Toxin Pharmaceutical currently does not have products or business related to brain-computer interface fields [1] Photovoltaics - Zerun New Energy has not yet conducted research and development on solar wing junction boxes [1] Media - Bona Film Group is involved in the production of "Fast and Furious 3," which is scheduled for nationwide release during the 2026 Spring Festival [1] Other - Taihe Technology's renovation of its original lithium iron phosphate production facility is expected to achieve an annual production capacity of 10,000 tons of sodium iron phosphate [1] - Li'ang Technology will continue to increase R&D investment in computing power, cloud computing, and cloud services [1] - Xinwei Communication currently holds a 15% stake in Xinwei Electric Science [1] - Boss Software is still held by Linzhi Tencent [1] - Xinke Mobile's satellite internet business is still in the investment phase [1] - Beijing Junzheng's new process products are expected to begin large-scale sales starting in the first quarter [1] - Xinbao Co.'s self-branded coffee machine Barsetto has a small domestic sales proportion [1]